logo

Rigel Pharmaceuticals Inc. (RIGL)



Trade RIGL now with
  Date
  Headline
11/6/2018 4:05:09 PM Rigel Pharmaceuticals Q3 Loss/share $0.14, Same As Last Year
10/29/2018 8:05:10 AM Rigel Pharma Enters Deal With Kissei Pharma To Commercialize TAVALISSE In Japan And Other Asian Countries
10/29/2018 8:04:03 AM Rigel Pharma Enters Collaboration And License Agreement With Kissei Pharma
10/11/2018 7:33:20 AM Rigel Receives EMA Validation Of Marketing Authorization Application For Fostamatinib Disodium Hexahydrate
8/8/2018 4:10:25 PM Rigel Pharmaceuticals Q2 Loss/share $0.16, Same As Last Year
6/26/2018 7:30:50 AM Rigel Begins Phase 1 Study To Assess R835 In Healthy Subjects
6/12/2018 7:31:12 AM Rigel To Present Oral Presentation On Phase 2 Stage 1 Interim Results For Fostamatinib
5/30/2018 7:31:32 AM Rigel Appoints Dean Schorno EVP And CFO
5/29/2018 7:30:57 AM Rigel Announces Availability Of TAVALISSE In U.S.
5/1/2018 4:04:06 PM Rigel Pharma Q1 Loss Per Share $0.17 Vs Loss $0.13 Last Year